Creative Medical Technology Holdings
-
Biologics
Creative Medical Technology Announces Peer Reviewed Publication of Positive Results for StemSpine® Study
–Two-Year Follow-Up Results Confirm Significant Efficacy and No Serious Adverse Effects in Patients who Underwent the StemSpine® Procedure for Treating…
Read More » -
Biologics
StemSpine® to Launch in the United States Following Successful Treatments Overseas with 12+ Months Data Showing Safety and Efficacy
PHOENIX, Oct. 17, 2019 /PRNewswire/ — Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on Urology, Neurology and…
Read More »